AU2003211820A1 - NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES - Google Patents

NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES

Info

Publication number
AU2003211820A1
AU2003211820A1 AU2003211820A AU2003211820A AU2003211820A1 AU 2003211820 A1 AU2003211820 A1 AU 2003211820A1 AU 2003211820 A AU2003211820 A AU 2003211820A AU 2003211820 A AU2003211820 A AU 2003211820A AU 2003211820 A1 AU2003211820 A1 AU 2003211820A1
Authority
AU
Australia
Prior art keywords
wnt
diseases
treatment
application
novel function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003211820A
Inventor
Takahiro Fujino
Juro Sakai
Tokuo Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Publication of AU2003211820A1 publication Critical patent/AU2003211820A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003211820A 2002-03-08 2003-03-07 NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES Abandoned AU2003211820A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-64458 2002-03-08
JP2002064458A JP2005220022A (en) 2002-03-08 2002-03-08 NEW ACTION OF Wnt AND ITS APPLICATION TO TREATMENT OF DISEASE
PCT/JP2003/002719 WO2003075948A1 (en) 2002-03-08 2003-03-07 NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES

Publications (1)

Publication Number Publication Date
AU2003211820A1 true AU2003211820A1 (en) 2003-09-22

Family

ID=27800217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003211820A Abandoned AU2003211820A1 (en) 2002-03-08 2003-03-07 NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES

Country Status (3)

Country Link
JP (1) JP2005220022A (en)
AU (1) AU2003211820A1 (en)
WO (1) WO2003075948A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047330A1 (en) * 2007-10-12 2009-04-16 Universite Louis Pasteur Use of wnt5a for treating or preventing obesity and atherosclerosis
US10520494B2 (en) * 2014-03-26 2019-12-31 Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Flattop (FLTP) is a novel biomarker for beta cell maturation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545137B1 (en) * 1997-04-15 2003-04-08 John A. Todd Receptor

Also Published As

Publication number Publication date
WO2003075948A1 (en) 2003-09-18
JP2005220022A (en) 2005-08-18

Similar Documents

Publication Publication Date Title
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003257937A1 (en) Methods and compositions for treatment of dermal conditions
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003288902A1 (en) Microcapsules and methods of use
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
EP1571970A3 (en) Diagnosis and monitoring of diseases
HK1083062A1 (en) Treatment of diseases and conditions mediated by increased phosphorylation
AU2003301240A1 (en) Skin cleanser compositions and methods of use
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
IL166016A0 (en) Topical treatment of skin diseases
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003219580A1 (en) Novel therapeutical use of byakangelicin
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003270815A1 (en) Treatment of irritable bowel syndrome and related bowel diseases
AU2003211820A1 (en) NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES
AU2003222250A1 (en) Treatment of autoimmune diseases
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
AU2003279800A1 (en) Sulfatases and methods of use thereof
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003297570A1 (en) Treatment of skin diseases
AU2003250329A1 (en) Regulation of novel human asparagine-hydroxylases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase